Modernizing Perinatal Syphilis Testing
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Where
- Baltimore, Columbus, Houston, and Los Angeles, United StatesSee the 9 sites
- Trial code
- Status
- Recruiting
- People taking part
- 924 people, planned
- Started
- 2 May 2023
- Expected to end
- 30 Nov 2027
- Type of study
- Interventional
- Treatments tested
- Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum
- Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum
- Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis
- Record updated
- 3 November 2025
Who can take part
- Age
- Up to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Maternal diagnosis of syphilis by 2021 CDC STI guidelines, irrespective of treatment status; AND viable pregnancy with gestational age ≥ 12 weeks OR postpartum ≤ 96 hours from delivery OR Neonates of pregnancies affected by syphilis ≤ 72 hours of birth
- Individuals (men and non-pregnant) with syphilis in Harris Health clinic with syphilis
Who cannot take part
- Planning to move outside of study prior to ND testing
- Pregnant individuals and neonates who do not meet the criteria of syphilis (false positive)
This trial is currently available in United States.
- Johns Hopkins UniversityBaltimore, United StatesContact: Jeanne Sheffield, MDTaking people
- Kennedy Krieger InstituteBaltimore, United StatesContact: Alison Pritchard, PhDTaking people
- Nationwide Children's HospitalColumbus, United StatesContact: Pablo SanchezTaking people
- Baylor College of MedicineHouston, United StatesContact: Martha Rac, MDTaking people
- Christus HealthHouston, United StatesContact: James Hill, MDTaking people
- Texas Children's HospitalHouston, United StatesContact: Lisa Noll, PhDTaking people
- The University of Texas Health Science Center at HoustonHouston, United StatesContact: Norma Perez, DOTaking people
- University of California, Los AngelesLos Angeles, United StatesContact: Karin Best, PhDTaking people
- University of Southern CaliforniaLos Angeles, United StatesContact: Brendan Grubbs, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine the testing performance of real-time quantitative polymerase chain reaction and transcription mediated amplification by comparing test performance of these novel molecular tests to current 2021 CDC CS guidelines for maternal/neonatal dyads at risk for syphilis infection and to determine whether CS is associated with adverse neurodevelopmental outcomes.
The group in the trial
- Molecular testing for detection of T. pallidum and use of CDC guidelines for diagnosis of syphilisTreatment being tested
Treatment: Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum, Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum, and Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 November 2025